Angel Adegbesan

Novavax Inc .'s biggest one-day gain in more than 15 years is forcing some short sellers betting against the stock to exit their positions at a loss.

Novavax Inc.'s record one-day gain is forcing some short sellers betting against the stock to exit their positions at a loss.

Eli Lilly & Co. is down more than $120 billion in market value and its status as the poster child of the weight-loss drug frenzy is under threat with at least two rivals posting encouraging developments for their obesity treatments.

Emergent BioSolutions Inc. led an advance in the stocks of companies working on vaccines and antiviral products this week as investors await word from US regulators on if its smallpox vaccine can also be used for the fast-spreading mpox virus.

(Bloomberg) -- Emergent BioSolutions Inc. led an advance in the stocks of companies working on vaccines and antiviral products this week as investors await word from US regulators on if its smallpox vaccine can also be used for the fast-spreading mpox virus. Most Read from BloombergManchester Is Giving London a Run for Its MoneyBoston’s Broke and Broken Transit System Hurts Downtown RecoveryA Floating Island in Baltimore Raises Hope for a Waterfront RevivalA Warehouse Store Promises Housing for

Regeneron Pharmaceuticals Inc. shares are headed for their biggest monthly drop since mid-2022 after a legal setback that opens the door to an early launch of a competing therapy to the drugmaker’s blockbuster eye treatment, Eylea.

“Spring forward, fall back” is a twice-a-year part of life in roughly 70 countries around the world. In the US, where the practice is more than a century old, lawmakers are considering measures that would end clock changes and make daylight saving time permanent. That would mean later sunrises and sunsets for half the year. There’s evidence that the public health effect would be mixed: fewer car accidents and heart attacks caused by time shifts, but potentially a loss of sleep quality for almost

Most Read from Bloomberg Wave Life Sciences Ltd. said it achieved so-called proof-of-mechanism in a single-dose trial of its potential

Companies developing RNA-editing therapies are rallying Wednesday after breakthrough data from a clinical trial showed the technology’s promise as a treatment.

A recently debuted nursing home operator, PACS Group Inc., made a violent reversal this week, erasing around $2.5 billion from its cofounders’ fortunes.